Pfizer announced that it will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two separate publicly traded companies at this time.

“With this decision, our two distinct businesses will remain separately managed units within Pfizer, which we believe is currently the best structure,” stated Ian Read, chairman and chief executive officer.

The news is likely to disappoint some analysts and investors. But Pfizer’s overall long-term growth prospects may be stronger now than market watchers might have thought previously.